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The carbapenems represent important therapeutic 
options for serious infections caused by Pseudomonas 
aeruginosa. However, P. aeruginosa that are resistant 
to these antimicrobials have emerged and spread within 
hospital settings worldwide. This pathogen may become 
resistant to the carbapenems by modulating and combin-
ing different intrinsic mechanisms such as down regula-
tion or loss of porins, especially OprD, overexpression of 
efflux pumps, substantial production of its chromosomal 
AmpC β-lactamase and target alterations (Lister et al. 
2009). Alternatively, P. aeruginosa may acquire genes 
encoding metallo-β-lactamases (MBL), enzymes that 
are able to inactivate carbapenems efficiently and thus 
are considered the most clinically significant mechanism 
of carbapenem resistance in this species (Walsh 2008).
Over the last decades, different MBLs have been 
identified in P. aeruginosa from numerous geographic 
regions (Sacha et al. 2008). Noteworthy, carbapenem-
susceptible P. aeruginosa clinical isolates that carried 
MBL-encoding genes have been reported (Martins et 
al. 2007, Pellegrino et al. 2008, Naas et al. 2011). Clini-
cal isolates showing either diminished or no expression 
of MBL-encoding genes may present the carbapenem-
susceptible phenotype. In the above referenced reports, 
however, the expression of MBL-encoding genes was 
not determined (Martins et al. 2007, Pellegrino et al. 
2008, Naas et al. 2011). Nevertheless, these findings are 
worrisome since carbapenem-susceptible MBL produc-
ers may act as reservoirs of such resistance determinants 
with potential risk for silent spread. In the present paper, 
we report the occurrence of meropenem-susceptible P. 
aeruginosa clinical isolates producers of the MBL IMP-
16. The expression of genes associated with carbapenem 
resistance was investigated, as well as the genetic con-
text and location of the bla
IMP-16
 gene.
SUBJECTS, MATERIALS AND METHODS
Bacterial isolates - During 2003, two P. aeruginosa 
clinical isolates, namely Pa30 and Pa43, were recovered 
from different patients hospitalized in a teaching hospi-
tal located in the city of Londrina, southern Brazil. Pa30 
was isolated from a necrotic tissue culture of a 24 year-
old male patient presenting a surgical wound infection 
and Pa43 was recovered from the urine of a 54 year-old 
male patient with urinary tract infection. The genetic 
relatedness of Pa30 and Pa43 was evaluated by pulsed 
field gel electrophoresis (PFGE) of SpeI-digested DNA 
samples, as previously described (Picão et al. 2009).
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The aim of this study was to characterize two metallo-β-lactamases (MBLs)-producing Pseudomonas aeruginosa 
clinical isolates showing meropenem susceptibility. Antimicrobial susceptibility was assessed by automated testing 
and Clinical and Laboratory Standards Institute agar dilution method. MBL production was investigated by phe-
notypic tests. Molecular typing was determined by pulsed field gel electrophoresis (PFGE). MBL-encoding genes, 
as well as their genetic context, were identified by polymerase chain reaction (PCR) and sequencing. The location 
of bla
IMP-16 
was determined by plasmid electrophoresis, Southern blot and hybridization. Transcriptional levels of 
bla
IMP-16,
 mexB, mexD, mexF, mexY, ampC and oprD were determined by semi-quantitative real time PCR. The P. 
aeruginosa isolates studied, Pa30 and Pa43, showed imipenem and meropenem susceptibility by automated testing. 
Agar dilution assays confirmed meropenem susceptibility whereas both isolates showed low level of imipenem re-
sistance. Pa30 and Pa43 were phenotypically detected as MBL producers. PFGE revealed their clonal relatedness. 
bla
IMP-16 
was identified in both isolates, carried as a single cassette in a class 1 integron that was embedded in a plas-
mid of about 60-Kb. Pa30 and Pa43 overexpressed MexAB-OprM, MexCD-OprJ and MexXY-OprM efflux systems 
and showed basal transcriptional levels of ampC and oprD. MBL-producing P. aeruginosa that are not resistant to 
meropenem may represent a risk for therapeutic failure and act as silent reservoirs of MBL-encoding genes.
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Species identification, susceptibility testing and 
screening for carbapenemase production - Species identi-
fication and routine antibiogram of Pa30 and Pa43 isolates 
were performed using the MicroScan Walkaway automat-
ed system (Dade Behring, West Sacramento, CA) with 
Combo negative CN30 Panels. Antimicrobials tested in-
cluded piperacillin, piperacillin-tazobactam, ceftazidime, 
cefepime, aztreonam, imipenem, meropenem, amikacin, 
gentamicin, tobramycin and ciprofloxacin. Susceptibility 
profiles of isolates were confirmed by Clinical and Labo-
ratory Standards Institute (CLSI) agar dilution for amika-
cin, ciprofloxacin, ceftazidime, cefepime, imipenem and 
meropenem. P. aeruginosa ATCC 27853 and Escherichia 
coli ATCC 25922 strains were used as quality control in 
susceptibility testing assays (CLSI 2009, 2012).
MBL phenotypic detection, identification of MBL-en-
coding genes and analysis of their genetic environment 
- Isolates Pa30 and Pa43 were phenotypically screened 
for MBL production using both modified Hodge and 
double disk synergy tests, as previously described (Lee 
et al. 2003, Picão et al. 2008). A multiplex polymerase 
chain reaction (PCR) targeting the MBL-encoding genes 
bla
IMP
, bla
VIM
, bla
SPM
, bla
GIM 
and bla
SIM
 was performed, 
using previous published primers and cycling conditions 
(Mendes et al. 2007). The genetic environment of bla
IMP
 
was determined by PCR using the specific primers to 
anneal at the 5’ and 3’ conserved sequences of class 1 
integrons, followed by amplicon sequencing (Naas et al. 
2011). Sequencing reactions were performed using spe-
cific primers with automated ABI 3130 sequencer (Ap-
plied Biosystems, Foster City, CA). The nucleotide and 
deduced protein sequences were analyzed with online 
software available at the National Center for Biotechnol-
ogy Information website (ncbi.nlm.nih.gov).
Genetic location of bla
IMP-16
 - Plasmid extraction was 
performed by the Kieser technique (Kieser 1984). E. coli 
NCTC 50192 harbouring four plasmids of 154, 66, 38 
and 7-kb was used as molecular size marker in gel elec-
trophoresis assays. Hybridization of plasmid extracts 
was performed after gel electrophoresis and Southern 
blotting, which was performed by capillary transfer onto 
Hybond-N+ nylon membrane (GE Healthcare, UK). La-
belling of bla
IMP-16 
specific probe and signal detection 
were carried out using a nonradioactive labelling and de-
tection kit according to the manufacturer’s instructions 
(GE Healthcare, UK). 
Relative quantification of mRNA by real time PCR 
(RT-PCR) - Transcriptional levels of bla
IMP-16
 and also 
of genes encoding components of efflux pumps (mexB, 
mexD, mexF, mexY), chromosomal cephalosporinase 
(ampC) and OprD porin (oprD) were determined with 
a Mastercycler Realplex apparatus (Eppendorf, Germa-
ny). Total RNA was isolated from logarithmic cultures 
of each strain using the RNase Mini Kit, following the 
manufacturer’s recommendations (Qiagen, Hilden, Ger-
many). Five micrograms of total RNA was submitted to 
cDNA conversion using random primers by High Capac-
ity cDNA Archive Kit (Applied Biosystems, Foster City, 
USA). Semi-quantitative RT-PCR was performed with 
Platinum SYBR Green Supermix (Invitrogen, Carls-
bad, USA), using specific primers for the chromosomal 
genes mexB, mexD, mexF, mexY, ampC and oprD, as pre-
viously described (Xavier et al. 2010), and also for the 
acquired MBL-encoding gene, bla
IMP-16 
(Mendes et al. 
2007). Amplification was carried out in triplicate from 
cDNA preparations. The relative transcriptional levels 
were calculated according to ΔΔCT method by Realplex4 
software following the manufacture’s recommendations 
(Eppendorf, Germany). Briefly, the ΔΔCt method pro-
vides the relative gene expression levels by averaging 
cycle threshold (Ct) values from triplicate RT-PCR reac-
tions for the target and housekeeping genes. The range 
of expression levels obtained for the triplicates, which 
incorporates the standard deviation (SD) of the ΔΔCt 
value into the fold-difference, was used to calculate the 
confidence interval (CI) considering a confidence level 
of 95%. Additionally, in order to minimize the error 
and preserve the accuracy and robustness of this test, 
we have excluded and repeated those triplicate reactions 
whose average of Ct values had presented a SD value 
higher than 0.20. The rpsL endogenous gene was used as 
the housekeeping gene and the wild-type P. aeruginosa 
PA01 was used as the reference strain to determine the 
relative expression levels of those chromosomal genes, 
while, for the analysis of the acquired MBL-encoding 
gene expression, we have included as the reference 
strain a previously characterized IMP-16-producing P. 
aeruginosa (isolate 101-4704) which is fully resistant to 
carbapenems [imipenem and meropenem minimum in-
hibitory concentration (MICs), 256 µg/mL and 128 µg/
mL, respectively], ceftazidime (MIC > 256 µg/mL) and 
cefepime (MIC 64 µg/mL) (Mendes et al. 2004).
 The efflux systems MexAB-OprM, MexCD-OprJ, 
MexEF-OprN and MexXY-OprM were considered 
overexpressed when the transcriptional levels of mexB, 
mexD, mexE and mexY were at least two, 100, 100 and 4 
fold higher than those of the wild-type reference strain 
PAO1, respectively (Xavier et al. 2010). Reduced oprD 
expression and overexpression of ampC were considered 
relevant when their transcriptional levels were ≤ 70% 
and ≥ 10-fold, respectively, compared to that of the PAO1 
reference strain (Xavier et al. 2010). 
RESULTS
For surveillance purposes, during 2003, all ceftaz-
idime-resistant P. aeruginosa isolates recovered in a 
tertiary teaching hospital located in Londrina were 
screened for carbapenemase production. Isolates Pa30 
and Pa43 recovered in this period were initially subjected 
to automated susceptibility testing. Both isolates showed 
susceptibility to aztreonam, piperacillin-tazobactam, 
imipenem and meropenem but resistance to ceftazi-
dime, cefepime, ciprofloxacin, gentamicin and tobramy-
cin. Surprisingly, despite of their initial susceptibility to 
imipenem (MIC ≤ 4 µg/mL - by the time these isolate 
were tested, imipenem breakpoint for susceptibility was 
≤ 4 µg/mL), isolates Pa30 and Pa43 were phenotypi-
cally detected as MBL producers. Susceptibility testing 
determined by CLSI agar dilution confirmed resistance 
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to amikacin, ciprofloxacin, ceftazidime and cefepime 
(Table). In addition, both isolates showed susceptibility 
to meropenem, but resistance to imipenem (MIC 8 µg/
mL), level of resistance that was significantly lower than 
that shown by isolate 101-4704 (MIC 256 µg/mL). Pa30 
and Pa43 shared the same PFGE restriction pattern, indi-
cating their clonal origin (data not shown).
Pa30 and Pa43 isolates presented an amplicon 
consistent with the bla
IMP 
gene. Further sequencing 
identified the bla
IMP-16 
allele in both isolates. Analysis 
of bla
IMP-16
 genetic context revealed that both isolates 
carried this gene as a single cassette into the variable 
region of a class 1 integron. The integrase gene showed 
a GGG deletion between -10 and -35 boxes of P2 com-
pared to that of isolate 101-4704, possibly inactivating 
this promoter in isolates Pa30 and Pa43. In contrast, 
Pa30 and Pa43 harboured the putative weak Pc version 
(TGGACA-N17-TAAGCT), which was identical to the 
one identified in isolate 101-4704.
Hybridization experiments revealed that bla
IMP-16
 was 
carried by a plasmid of about 60-Kb in both Pa30 and 
Pa43. However, repetitive attempts to transfer pPa30 
and pPa43 by transformation performed as previously 
described were unsuccessful, regardless of the recipient 
strains used, either electrocompetent E. coli TOP10 or P. 
aeruginosa PA01 (data not shown) (Picão et al. 2009).
Semi-quantitative RT-PCR analysis showed that 
transcriptional levels of bla
IMP-16 
were similar in Pa30, 
Pa43 and 101-4704 isolates. In addition, Pa30, Pa43 and 
101-4704 showed transcriptional levels of oprD compa-
rable to that of the reference strain PA01, which might 
indicate normal expression of the OprD porin in these 
clinical isolates (Table). However, OMP analysis by so-
dium dodecyl sulfate polyacrylamide gel electrophoresis 
revealed the absence of a 49 kDa band in the protein pat-
tern of the 101-4704 isolate, while this structure was pre-
served in Pa30, Pa43 and PA01 strain (data not shown), 
indicating possible OprD loss in the carbapenem-resis-
tant isolate 101-4704. Analysis of ampC transcription 
suggested that Pa30 and Pa43 produced basal amounts 
of AmpC, whereas isolate 101-4704 overexpressed this 
cephalosporinase (Table). Regarding efflux pumps con-
stituents, mexB, mexD and mexY transcriptional levels 
were higher in Pa30 than in PA01, suggesting MexAB-
OprM, MexCD-OprJ and MexXY-OprM overexpres-
sion, respectively. Similarly, Pa43 showed mexD and 
mexY transcriptional levels significantly higher than 
those of PA01, but its mexB expression was near the cut-
off value for overexpression. The carbapenem-resistant 
P. aeruginosa producing IMP-16, isolate 101-4704, also 
showed increased transcriptional levels of mexB and 
mexY compared to PA01, indicating that the MexAB-
OprM and MexXY-OprM efflux systems were over-
expressed in this strain. Nevertheless, Pa30 and Pa43 
showed transcriptional levels of mexD and mexY signifi-
cantly higher than those of isolate 101-4704 which, in 
turn, showed mexB levels much higher than those of the 
former isolates (Table). The magnitude of transcription-
al levels differences for the analyzed genes considering 
an 95% CI is depicted in Figure.
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DISCUSSION
In this study, we have identified two MBL-producing 
P. aeruginosa clinical isolates that exhibited low level of 
imipenem resistance but susceptibility to meropenem. 
PFGE analysis revealed that those isolates were geneti-
cally related to each other. However, previous report 
about hypersusceptible phenotype in P. aeruginosa sug-
gested that this phenomenon is not inherent to one par-
ticular type of strain, once it has been observed among 
genetically unrelated clinical isolates (Wolter et al. 2009). 
Fortunately, the patients from whom the strains Pa30 and 
Pa43 were isolated were not seriously ill and showed 
clinical resolution of signs and symptoms after receiving 
ciprofloxacin and levofloxacin, respectively, for 14 days.
To date, IMP-16 production has only been identi-
fied in carbapenem-resistant Pseudomonas spp clinical 
isolates from Brazil (Mendes et al. 2004, Marra et al. 
2006, Carvalho-Assef et al. 2010, Scheffer et al. 2010). 
In this study, we have observed that bla
IMP-16 
transcrip-
tional level was similar among Pa30, Pa43 and 101-
4704, despite of the probable impaired P2 promoter in 
Pa30 and Pa43. Nevertheless, bla
IMP-16 
expression was 
not enough to confer high level of carbapenem resis-
tance in isolates Pa30 and Pa43. 
High level carbapenem resistance in strain 101-4704 
could be attributed not only to IMP-16 activity, but also 
to the OprD loss and the concomitant overexpression of 
AmpC and MexAB-OprM efflux system. It has been 
previously observed that mutants hyperexpressing the 
MexCD-OprJ efflux system usually show imipenem hy-
persusceptibility (Masuda et al. 1996, Wolter et al. 2005). 
Although the mechanism involved in such phenotype is 
unknown, it has been proposed that it is not related to 
OprD loss or AmpC repression (Wolter et al. 2005). One 
hypothesis is that the hyperexpression of mexCD-oprJ 
operon may be associated with downregulation of an 
uncharacterized efflux system that extrudes imipenem, 
since the P. aeruginosa genome contains several unchar-
acterized efflux pumps belonging to multiple families 
(Angus et al. 1982, Wolter et al. 2005). It is also possible 
that MexCD-OprJ hyperexpression could alter the com-
position or architecture of the outer membrane, increasing 
its permeability to carbapenems (Angus et al. 1982, Wolt-
er et al. 2005). Therefore, the hyperexpression of MexCD-
OprJ might have contributed to limit levels of carbapenem 
resistance in the isolates Pa30 and Pa43, although further 
analyses are necessary to confirm this hypothesis.
MBL detection has not been routinely performed in 
most clinical microbiology laboratories. Consequently, 
the occurrence of MBL production in P. aeruginosa that 
remain susceptible to meropenem might be unrecog-
nized by the clinical laboratories. It might lead to un-
derestimation of MBL prevalence in the clinical setting. 
In this manner, these MBL producers might act as silent 
reservoirs of such resistance determinants, with ability 
to spread, since MBL-encoding genes are often carried 
by mobile genetic elements. In addition, failing in de-
tecting MBL production among meropenem-susceptible 
isolates may lead to inadequate prescription of this drug 
and possible therapeutic failure in seriously ill patients.
In 2010, the CLSI revised the Enterobacteriaceae 
clinical breakpoints for carbapenems in order to over-
come the problematic emergence of KPC producers that 
might be categorized as susceptible to these antimicro-
bial agents (CLSI 2010). More recently, the carbapenems 
clinical breakpoints for P. aeruginosa were also revised 
(CLSI 2012). Based on the findings reported here, al-
though the CLSI initiative avoided the miscategorization 
of the MBL producers Pa30 and Pa43 as susceptible to 
imipenem, these isolates were still categorized as mero-
penem-susceptible. It might be difficult to establish the 
correct breakpoint that would certainly detect complex 
isolates like Pa30 and Pa43, or others that might appear 
even more susceptible to carbapenems due to other fac-
tors. Identification of carbapenemase producers could 
also rely upon phenotypic detection, especially in regions 
where MBL-producing isolates are prevalent. However, 
the implementation of such recommendation has been 
jeopardized by the lack of a consensus regarding the cri-
terion to select isolates for screening, the method, the 
β-lactam substrates and the best inhibitor combinations 
to be employed for precise MBL phenotypic detection. 
Although much progress has been achieved in compre-
hending the mechanisms of antimicrobial resistance, it 
is imperative that the scientific community concentrates 
efforts in developing means to assess the real prevalence 
of carbapenemase producers. It is also very important to 
evaluate its clinical impact and establish whether car-
bapenems would be appropriate to treat infections due 
to carbapenemase producers that are still categorized as 
susceptible to these antimicrobials.
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